Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 303 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "biochemical recurrence" Condition: Prostate Cancer Clear all
Completed Phase 3 Interventional Results available

Radiation Therapy in Treating Patients With Stage II Prostate Cancer

NCT00331773
View directory record Official record
Conditions
Prostate Cancer
Interventions
Conventional 3D-CRT or IMRT, Hypofractionated 3D-CRT or IMRT
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
1,116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
282
States / cities
Phoenix, Arizona • Tucson, Arizona • Auburn, California + 200 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Jul 23, 2026, 8:17 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Jul 23, 2026, 8:17 AM EDT
Active, not recruiting No phase listed Observational

Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing

NCT04404894
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
7
States / cities
Homewood, Alabama • Long Beach, California • Bradenton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jul 23, 2026, 8:17 AM EDT
Completed Phase 2 Interventional

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

NCT02020070
View directory record Official record
Conditions
Metastatic Castration Sensitive Prostate Cancer
Interventions
Degarelix, Ipilimumab, Radical Prostatectomy
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 8:17 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy

NCT00002874
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, radiation therapy, placebo
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Male only
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2022
U.S. locations
221
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 168 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Jul 23, 2026, 8:17 AM EDT
Active, not recruiting Phase 2 Interventional

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

NCT04114825
View directory record Official record
Conditions
Prostate Cancer Recurrent
Interventions
RV001V, Placebo
Biological · Other
Lead sponsor
RhoVac APS
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Clearwater, Florida • Towson, Maryland • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Jul 23, 2026, 8:17 AM EDT
Recruiting No phase listed Observational

Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

NCT01961713
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 23, 2026, 8:17 AM EDT
Completed No phase listed Observational

Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer

NCT03159676
View directory record Official record
Conditions
Prostate Cancer
Interventions
Proton beam
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Timeline
2017 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 23, 2026, 8:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

NCT03490032
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
[68Ga]-PSMA-R2
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Jul 23, 2026, 8:17 AM EDT
Active, not recruiting Not applicable Interventional

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

NCT04396808
View directory record Official record
Conditions
Prostate Cancer
Interventions
Decipher, Prolaris, Oncotype Dx Genomic Prostate Score (GPS), Standard of care (askMUSIC score)
Device · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
8
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 23, 2026, 8:17 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

NCT00936390
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
499
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 23, 2026, 8:17 AM EDT
Active, not recruiting Not applicable Interventional

Daily Adaptive Post-Prostatectomy With Stereotactic Ablative Radiotherapy in Patients With Prostate Cancer

NCT05830838
View directory record Official record
Conditions
Malignant Prostate Neoplasm
Interventions
Computed Tomography, Image-Guided Adaptive Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 23, 2026, 8:17 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer

NCT02508636
View directory record Official record
Conditions
Prostatic Neoplasms, Pelvic Nodal
Interventions
Enzalutamide, Leuprolide, Intensity-Modulated Radiation Therapy
Drug · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Jul 23, 2026, 8:17 AM EDT
Recruiting Phase 3 Interventional

Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment

NCT07293585
View directory record Official record
Conditions
Prostate Cancer
Interventions
Neurovascular sparing stereotactic body radiation therapy
Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jul 23, 2026, 8:17 AM EDT
Recruiting Phase 2 Interventional

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

NCT06391034
View directory record Official record
Conditions
Prostate Cancer
Interventions
hyperpolarized pyruvate +/-urea (13C/15N), Non-investigational External beam radiotherapy (EBRT), Radiotherapy (RT), Multi-parametric magnetic resonance imaging (mpMRI), Non-interventional hormone therapy, Prostate Biopsy
Drug · Radiation · Procedure + 1 more
Lead sponsor
Robert Bok, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 23, 2026, 8:17 AM EDT
Withdrawn Phase 2 Interventional

Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer

NCT02811809
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, IHT
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Jul 23, 2026, 8:17 AM EDT
Active, not recruiting Phase 2 Interventional

A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer

NCT04190446
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Intensity-Modulated Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection
Radiation · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 23, 2026, 8:17 AM EDT
Completed Phase 1 Interventional Results available

Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer

NCT02555397
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ad5-yCD/mutTKSR39rep-hIL12
Biological
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Jul 23, 2026, 8:17 AM EDT
Completed Not applicable Interventional

Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer

NCT01117935
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
intensity modulated external beam radiation therapy
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Jul 23, 2026, 8:17 AM EDT
Not listed Not applicable Interventional

A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)

NCT00772317
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
High Intensity Focused Ultrasound
Device
Lead sponsor
SonaCare Medical
Industry
Eligibility
40 Years to 85 Years · Male only
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Naples, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Jul 23, 2026, 8:17 AM EDT
Completed Phase 2Phase 3 Interventional

Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer

NCT00765479
View directory record Official record
Conditions
Prostate Cancer
Interventions
soy protein isolate, placebo
Dietary Supplement · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Jul 23, 2026, 8:17 AM EDT
Terminated No phase listed Observational

Prospective Prolaris Value and Efficacy

NCT03152448
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prolaris
Behavioral
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
12
States / cities
San Diego, California • West Haven, Connecticut • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2022 · Synced Jul 23, 2026, 8:17 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients

NCT02611882
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 labeled HBED-CC PSMA, Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT), Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)
Drug · Device
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older · Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Jul 23, 2026, 8:17 AM EDT
Completed No phase listed Observational

Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer

NCT00176579
View directory record Official record
Conditions
Osteoporosis, Prostate Cancer
Interventions
dual x-ray absorptiometry
Procedure
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
50 Years to 75 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Jul 23, 2026, 8:17 AM EDT